| Literature DB >> 35606796 |
Tosséa A Stéphane Koui1,2, Alloh Albert Gnondjui1,2, Adji Eric Gbessi1,2, Ako Aristide Bérenger Ako2, Baba Coulibaly1,2, A Delpêche Aka1,2, Bi Sery E Gonedele1, Offiana André Toure2, Ronan Jambou3,4.
Abstract
BACKGROUND: Sickle cell disease (SCD) is a hemoglobin disorders that concern 300,000 newborns each year around the world. There are hemoglobin haplotypes that affect SCD clinic expression.Entities:
Keywords: Haplotype; Ivory coast; Malaria; Sickle cell anemia
Mesh:
Substances:
Year: 2022 PMID: 35606796 PMCID: PMC9125897 DOI: 10.1186/s12920-022-01263-3
Source DB: PubMed Journal: BMC Med Genomics ISSN: 1755-8794 Impact factor: 3.622
Primers used in this study
| Primer name | Primer sequence | Source |
|---|---|---|
| 5’ Gγ | AACTGTTGCTTTATAGGATTT T | [ |
| AGGAGCTTATTGATAACCTCAGAC | ||
| Gγ | TGCTGCTAATGCTTCATTACA A | |
| AAGTGTGGAGTGTGCACATGA | ||
| Aγ | TGCTGCTAATGCTTCATTACA A | |
| TAA ATGAGGAGCATGCACACA C | ||
| Ψβ | GAA CAG AAG TTG AGA TAG AGA | |
| ACT CAG TGG TCT TGT GGG CT | ||
| 3’Ψβ | TCT GCA TTT GAC TCT GTT AGC | |
| GGA CCC TAA CTG ATA TAA CTA | ||
| 3’ δ | TGG ATT CTG CCT AAT AAA A | |
| GGG CCT ATG ACA GGG TAA T | ||
| Β | GCT GAG GGT TTG AAG TCC AA | [ |
| CAC TGA TGC AAT CAT TCG TC | ||
| 5' β | CTACGCTGACCTCATAAATG | |
| CTAATCTGCAAGAGTGTCT | ||
| 3' β | TTCATACATAACAATACTCA | |
| GAGGAGAGCTTTACTTCCAA |
Hemoglobin Haplotypes restriction profiles described and in this study
| Gene and restriction enzyme | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 5gamma (XmnI) | Gamma (HindIII) | Alpha (HindIII) | phiBêta (HincII) | 3phiBêta (HincII) | 3Delta (HinfI) | Beta (AvaII) | 5Beta (HinfI) | 3Beta (HpaI) | |
| Senegal | + | + | − | + | + | + | + | + | + |
| Benin | − | − | − | − | + | − | + | + | − |
| Bantu (CAR) | − | + | − | − | − | − | + | + | + |
| Cameroon | − | + | + | − | + | + | + | − | + |
| Arabic | + | + | − | + | + | − | + | − | + |
| Atypic 1(1) * | − | − | − | − | + | + | + | + | + |
| Atypic 1(4) * | − | − | − | − | + | + | + | + | + |
| Atypic 2(6) * | − | + | − | − | + | + | + | + | + |
| Atypic 3(4) * | − | + | − | − | + | − | + | + | + |
| Atypic 4(1) * | − | − | − | − | + | − | + | + | + |
| Atypic 2(4) * | − | + | − | − | + | + | + | + | + |
+ = Presence of restriction enzyme site / − = Absence of restriction enzyme site
CAR Central African Republic
*() Proportion of allele, N = 20 atypics alleles
Fig. 1Gamma PCR products digestion by HindIII (Restriction Enzyme). PCR product size for Gamma is 782 pb xhich gives two fragments of 436 pb and 346 pb. After digestion by HindIII. Homozygote sample will present only 782 pb lane or 436 pb and 346 pb. Heterozygote sample will present three (03) lanes: 782 pb, 436 pb and 346 pb. On this gel, for example, homozygotes samples without restriction site of HindIII are N°7, N°9, N°12, N°18 and N°24. Homozygotes with restriction site are N°2, N°11, N°15 and N°23. All other are heterozygotes
Distribution of haplotype according malaria and hemoglobin typing
| Mean | Hemoglobin typing (N*) | Total (N*) | |||||
|---|---|---|---|---|---|---|---|
| AA | AC | AS | CC | SC | |||
| Benin/Atypic | 44,644 | 14 | 1 | 15 | |||
| Benin/Benin | 40,342 | 20 | 1 | 1 | 1 | 23 | |
| Cameroon/Benin | 43,768 | 2 | 2 | ||||
| Senegal/Benin | 31,017 | 6 | 1 | 7 | |||
| 42 | 3 | 1 | 1 | 47 | |||
| Atypic/Bantu | 84,307 | 1 | 1 | ||||
| Bantu/Bantu | 75,460 | 5 | 1 | 6 | |||
| Senegal/Bantu | 21,866 | 1 | 1 | ||||
| 7 | 1 | 8 | |||||
| Bantou/Benin | 48,930 | 36 | 5 | 1 | 1 | 43 | |
| Atypic/Atypic | 36,279 | 2 | 2 | ||||
| Total | 46,376** | 87 | 8 | 2 | 1 | 2 | 100 |
Data are available at https://ega-archive.org/studies/EGAS00001006008
*N: Proportion of participants; **Mean of parasitaemia in this study